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Abstract 
Objective: To determine if cervical ripening with the prostaglandin E 2analogue dinoprostone effectively shortens the induction- 
to-delivery interval in midpregnancy terminations with sulprostone. Study design: We retrospectively studied 100 women admitted 
for pregnancy termination atmidgestation because of fetal anomalies between September 1989 and January 1993. Three regimens 
were used: 27 women received intramuscular sulprostone only, 29 women received intravenous sulprostone only, and 44 women 
received intravenous sulprostone after cervical priming with dinoprostone. Wilcoxon's rank sum test was used for statistical analy- 
sis. Results: Dinoprostone priming did not significantly reduce the induction-to-delivery interval in either parous or nulliparous 
women. However, when divided into first and subsequent pregnancies, we found that primigravidae, but not multigravidae, had 
an induction-to-delivery interval that was significantly shorter by approximately 10.5 h when pretreated with dinoprostone. Conclu- 
sion: Dinoprostone priming of the cervix prior to termination of midgestation pregnancy with sulprostone (Nalador) effectively 
shortens the induction-to-delivery interval in women in their first pregnancy. 
Keywords: Sulprostone; Prostaglandin; Second trimester abortion; Pregnancy termination; Dinoprostone; Midgestation ter- 
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1. Introduction 
Termination of second trimester pregnancy for fetal 
anomalies is commonly carried out in Europe with the 
use of the prostaglandin analogue, 16-phenoxy- 17,18, 
19,20 tetranor PGE2 methylsulphonamide (sulprostone, 
Nalador~). Sulprostone can either be given as con- 
tinuous intravenous infusion or by repeated intra- 
muscular injections. Because continuous intravenous in- 
fusion is easier to control, produces less side effects and 
requires a lower total dose, continuous intravenous infu- 
sion has replaced intramuscular injections in recent 
years [1]. 
Cervical application of prostaglandin E2 (dinopro- 
stone, Cerviprost ®) has been used both for ripening of 
the cervix prior to induction of labour at term [21 and 
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prior to first trimester termination of pregnancy [3]. 
Based on the idea that intracervical dinoprostone might 
facilitate termination of second trimester pregnancy 
with the use of sulprostone, and some encouraging 
earlier eports [4-6], patients who were admitted for ter- 
mination of midgestation pregnancy with sulprostone 
were routinely pretreated with dinoprostone at our De- 
partment of Gynaecology from July 1991 onwards. 
To evaluate if priming of the cervix with dinoprostone 
indeed effectively shortens the time to delivery of the 
fetus after the initiation of sulprostone administration, 
we retrospectively analysed the data of women admitted 
for termination of pregnancy. 
2. Materials and methods 
In a retrospective study we analysed the data of 100 
consecutive women who were admitted for termination 
of pregnancy on the basis of structural and chromo- 
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somal fetal anomalies at the University Hospital, Rot- 
terdam. In the period from September 1989 to January 
1993, three different regimens were used in a more or 
less chronological order: (1) Repeated intramuscular in- 
jections of sulprostone, at the rate of one injection of 
500/~g every 4 h for 24 h, followed by a sulprostone-free 
interval of 24 h. This regimen was repeated until deliv- 
ery; (2) Continuous intravenous infusion of sulprostone 
at the rate of 2 t~g/min for 24 h, followed by a 
sulprostone-free interval of 24 h. This regimen was re- 
peated until delivery; (3) Continuous intravenous infu- 
sion of sulprostone identical to Regimen 2 was initiated 
12-16 h after a single intracervical dose of 0.5 mg 
dinoprostone, if the patient had not delivered within 
that time. 
We studied the interval between initiation of sulpros- 
tone therapy and the expulsion of the fetus for the three 
regimen groups. We performed two analyses: one based 
on a division according to parity and one based on a di- 
vision into primigravidae vs. multigravidae. We report 
median values and ranges, and we used the Wilcoxon's 
rank sum test and the Chi-square test for statistical anal- 
ysis. A P-value of < 0.05 was taken as the level of signif- 
icance. 
3. Resalts 
A total of 100 women were admitted to the University 
Hospital, Rotterdam, for termination of midgestation 
pregnancy after diagnosis of a congenital nomaly of the 
fetus. From September 1989 until July 1991, Regimen 1 
or 2 were used in 56 of these patients, 19 nulliparae and 
37 parae; from July 1991 until January 1993 Regimen 3 
was used in 44 patients, 22 nulliparae and 22 parae. All 
patients who underwent termination delivered vaginally 
without major side effects of the medication, or any 
other major complication. 
Table 1 shows the differences in gestational ge and 
interval between the initiation of sulprostone treatment 
and delivery, according to parity and regimen. There 
were no significant differences in gestational age be- 
tween subgroups. The induction-to-delivery interval was 
lower in parous than in nulliparous women (by approx- 
imately 8.5 h). The difference in interval between parous 
and nulliparous women was significant in the women 
treated with sulprostone only (approximately 10 h), but 
not in those women pretreated with dinoprostone (ap- 
proximately 4.5 h). In the dinoprostone pretreated 
group two women (one nullipara and one para) deliv- 
ered before sulprostone induction was initiated. 
Although the women who were pretreated with 
dinoprostone t nded to have shorter intervals than the 
women who were treated with sulprostone only (by ap- 
proximately 8 h for nulliparae and 2 h for parae), these 
differences were not significant, both compared to sul- 
prostone i.v. only and to sulprostone i.v. and i.m. com- 
bined, due to marked variation between individuals. 
Of the total group of 41 nulliparae, 31 were 
primigravida t the time of pregnancy termination and 
10 were in their second or subsequent pregnancy. Of 
these women, one had a spontaneous abortion plus 
dilatation and curettage, four women had an elective 
abortion through vacuum curettage, one woman had a 
previous midgestation termination with sulprostone; the 
other women had a history of a combination of these. 
Table 2 shows the differences in gestational ge and 
induction-to-delivery interval, according to gravidity 
and regimen. There were no significant differences in 
gestational age between subgroups. The induction-to- 
delivery interval was significantly shorter in multi- 
gravidae than in primigravidae by approximately 7 h. 
The difference in interval between multigravidae and 
primigravidae was significant in the women treated with 
sulprostone only (approximately 10 h), but not in those 
Table 1 
Differences in gestational age and the interval between i itiation of suiprostone treatment and delivery, for nuUiparae and parae 
Sulprostone i .m.  Sulprostone i .v . Dinoprostone + sulprostone i.v. Total 
Nulliparae 
Number 9 10 22 41 
Gestational ge (weeks) 18 5/7 18 0/7 19 2/7 19 0/7 
(15 6/7-23 0/7) (14 1/7-22 5/7) (15 0/7-23 2/7) (14 1/7-23 2/7) 
Interval to delivery (h) 23.25 (9.38-47.08) 23.63 (8.92-70.83) 15.58 (0.00-88.17) 21.00 (0.00-88.17) 
Vmrae 
Number 18 ! 9 22 59 
Gestational ge (weeks) 18 4/7 18 6/7 18 4/7 18 5/7 
(13 4/7-21 0/7) (15 6/7-23 0/7) (14 0/7-22 5/7) (13 4/7-23 0/7) 
Interval to delivery (h) 13.92" (3.25-42.58) 12.92" (5.25-62.75) 11.00 (0.00-71.50) 12.55" (0.00-71.50) 
Median value with ranges in brackets. 
*P < 0.05 compared with nulliparae. No significant differences between treatment groups. 
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Table 2 
Differences in gestational age and the interval between initiation of sulprostone treatment and delivery, for primigravidae and multigravidae 
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Sulprostone i.m. Sulprostone i.e. Dinoprostone + sulprostone i.e. Total 
Primigmvidne 
Number 8 8 15 31 
Gcstational ge (weeks) 18 5/7 18 5/7 19 2/7 19 0/7 
(15 6/7-23 0/7) (15 0/7-22 5/7) (15 0/7-23 2/7) (15 0/7-23 2/7) 
Interval to delivery (h) 23.13 (9.38-47.08) 24.67 (8.92-70.83) 14.00" (0.00-88.17) 19.75 (0.00-88.17) 
Mu~Igravidae 
Number 19 21 29 69 
Gcstational age (weeks) 18 4/7 18 5/7 18 6/7 18 5/7 
(13 4/7-21 0/7) (14 1/7-23 0/7) (14 0/7-23 0/7) (13 4/7-23 0/7) 
Interval to delivery (h) 14.33"* (3,25-42.58) 12.92"* (5.25-62.75) 13.00 (0.00-71.50) 13.00"* 
(0.00-71.50) 
Median value with ranges in brackets. 
*P < 0.05 compared with sulprostone only. 
**P < 0.05 compared with primigravidae. 
women pretreated with dinoprostone (approximately 1 
h). In the dinoprostone pretreated group, two women 
(one primigravida and one multigravida) delivered 
before sulprostone induction was initiated. In primi- 
gravidae who received pretreatment with dinoprostone, 
the induction-to-delivery interval was significantly 
reduced (by approximately 10.5 h) as compared to 
women who received sulprostone only, both compared 
to sulprostone i.e. only and to sulprostone i.v. and i.m. 
combined. In multigravidae, pretreatment with dino- 
prostone did not result in a significant reduction of the 
induction-to-delivery interval. 
Seventy-eight women, 28 of 41 nulliparae (68%) and 
50 of 59 parae (85%), 21 of 31 primigravidae (68%) and 
57 of 69 (83%) multigravidae, delivered within 24 h after 
initiation of sulprostone treatment. A significantly 
higher percentage of nulliparous women delivered < 24 
h after initiation of sulprostone treatment following 
dinoprostone priming (18/22, 82%) than without prim- 
ing (10/19, 53%). Similarly, a significantly higher percen- 
tage of primigravidae delivered < 24 h after initiation of 
sulprostone priming (13/15, 87%) than without priming 
(8/16, 50%). Dinoprostone priming had no significant 
effect on the chance to deliver < 24 h after the initiation 
of sulprostone treatment in parae and multigravidae. 
4. Discussion 
If it is necessary to terminate a pregnancy inmidgesta- 
tion, it is desirable that the technique of termination is
optimally effective, with minimal side effects. Therefore, 
the duration of hospital admission and the interval from 
initiation of treatment to delivery should be as short as 
possible. In addition, a recent study has shown that an 
infusion rate of sulprostone half that of which was used 
in the present study is also effective [1]. Although the in- 
tramuscular route of sulprostone is no longer used be- 
cause of the risk of overdosage, our study shows that 
intramuscularly and intraveneously administered sul- 
prostone are equally effective. 
In term pregnancies, ripening of the cervix with local- 
ly applied prostaglandin E2 facilitates induction of la- 
bour and reduces the induction-to-delivery interval [2]. 
It is not well known whether this also applies to midterm 
pregnancy. Several investigators have attempted to im- 
prove upon the technique of midgestation termination 
with the use of prostaglandins, and report a favorable 
effect of pretreatment ei her through vaginal application 
of prostaglandin E 2 tablets [4] or cervical application of 
sulprostone gel, prostaglandin E 2 or F2~ gel [5,6]. How- 
ever, these studies all lack a control group, which limits 
their importance. 
We found that the induction-to-delivery interval after 
sulprostone in midgestation is much shorter in multi- 
gravidae and parae compared to primigravidae and 
nulliparae. Apparently, the cervix dilates more easily 
after it has been previously dilated. Given the already 
short induction-to-delivery interval in multigravidae 
and parae it may not be surprising that the interval is 
not significantly shortened any further by pretreatment 
of the cervix with a locally applied, but weaker, pro- 
staglandin analogue. 
Our observation that pretreatment with dinoprostone 
does significantly reduce the induction-to-delivery inter- 
val in primigravidae but not in nulliparae suggests that 
it makes little difference as to how the cervix has 
previously been artificially dilated. Because all of the 10 
multigravidae nulliparae had experienced an artificial 
type of dilatation, it is uncertain to what extent a pre- 
vious spontaneous abortion alone, without dilatation, 
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might affect he response to dinoprostone pretreatment 
in a subsequent pregnancy. 
Although only a prospective, placebo-controlled, ran- 
domized trial can answer definitively the question to 
what extent cervical priming with dinoprostone shortens 
the induction-to-delivery interval in midpregnancy ter- 
mination with sulprostone, our retrospective study 
strongly suggests that pretreatment with dinoprostone is 
indeed effective in primigravidae. When dinoprostone 
on this indication is administered on an outpatient basis, 
in primigravidae the duration of hospitalization for sul- 
prostone termination in midpregnancy an be reduced. 
References 
[1] Kanhai H, Keirse M. Low-dose sulprostone for pregnancy ter- 
mination in cases of fetal abnormality. Prenat Diagn 1993; 13: 
ll7-121. 
[2] Rayburn W. Prostaglandin E 2 gel for cervical ripening and in- 
duction of labor: a critical analysis. Am J Obstet Gynecol 1989; 
160: 529-534. 
[3] Christensen NJ, Bygdeman M, Green K. Comparison of dif- 
ferent prostaglandin analogues and laminaria for preoperative 
dilatation of the cervix in late trimester abortion. Contraception 
1983; 27: 51-61. 
[4] Mursch G, Kassowitz C, Arzt W, Fr61ich H. Prostaglandine zur 
Schwangerschafsbeendigung m 2. und 3. Trimenon. Geburtsh u
Frauenheilk 1988; 48: 893-895. 
[5] Griinberger W, Husslein P. Kombinierte perizervikale und in- 
tramuskul/ire Prostaglandin Medikation zur Schwangerschafts- 
beendigung im II. und IIl. Trimenon. Geburtsh u Frauenheilk 
1983; 43: 240-244. 
[6] Rath W, UIbrich R, Kuhn W. Zervixreifung und Weheninduk- 
tion beim Schwangerschaftsabbruch im rnittleren und sp/iten II. 
Trimenon mittels intrazervikaler und extraamnialer Prostaglan- 
dingel Applikation. Wien Klin Wochenschr 1985; 97: 486-493. 
